Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: siRNA therapeutics - Silence Therapeutics

Drug Profile

Research programme: siRNA therapeutics - Silence Therapeutics

Alternative Names: Atu014; Atu093; Atu111; Atu134; Atu150; Atu195; AtuRNAi; Soluble Fms-like Tyrosine Kinase-1-specific SiRNA

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Atugen AG
  • Developer Charite of Berlin; McGill University; Sanofi; Silence Therapeutics; Silence Therapeutics plc
  • Class Antihyperglycaemics; Antihypertensives; Antineoplastics; Small interfering RNA
  • Mechanism of Action Endothelin A receptor antagonists; Protein kinase N3 inhibitors; RNA interference; Vascular endothelial growth factor receptor-1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute lung injury; Solid tumours

Highest Development Phases

  • Preclinical Preeclampsia; Pulmonary arterial hypertension
  • No development reported Acute lung injury
  • Discontinued Diabetes mellitus; Solid tumours; Wounds

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-lung-injury in Germany (Parenteral)
  • 14 Sep 2017 Preclinical trials in Preeclampsia in England (IV)
  • 14 Sep 2017 Pharmacodynamics data from a preclinical study in Preclampsia presented at the Council on Hypertension Scientific Session 2017 (AHA-ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top